Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 102

1.

NFE2L2 is associated with NQO1 expression and low stage of hepatic fibrosis in patients with chronic hepatitis C.

Wójcik KM, Piekarska A, Szymańska B, Jabłonowska E.

Adv Clin Exp Med. 2019 Mar 28. doi: 10.17219/acem/105852. [Epub ahead of print]

PMID:
30929321
2.

Transmission patterns of HIV-1 non-R5 strains in Poland.

Smoleń-Dzirba J, Rosińska M, Kruszyński P, Janiec J, Cycoń M, Bratosiewicz-Wąsik J, Beniowski M, Bociąga-Jasik M, Jabłonowska E, Szetela B, Wąsik TJ.

Sci Rep. 2019 Mar 21;9(1):4970. doi: 10.1038/s41598-019-41407-7.

3.

Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA.

Amele S, Peters L, Sluzhynska M, Yakovlev A, Scherrer A, Domingo P, Gerstoft J, Viard JP, Gisinger M, Flisiak R, Bhaghani S, Ristola M, Leen C, Jablonowska E, Wandeler G, Stellbrink H, Falconer K, D'Arminio Monforte A, Horban A, Rockstroh JK, Lundgren JD, Mocroft A; EuroSIDA study group.

HIV Med. 2019 Apr;20(4):264-273. doi: 10.1111/hiv.12711. Epub 2019 Feb 8.

PMID:
30734998
4.

Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients.

Jabłonowska E, Siwak E, Bociąga-Jasik M, Gąsiorowski J, Kalinowska A, Firląg Burkacka E, Wójcik-Cichy K, Piątek A, Cielniak I, Horban A.

PLoS One. 2019 Jan 17;14(1):e0210476. doi: 10.1371/journal.pone.0210476. eCollection 2019.

5.

Dual therapy based on raltegravir and boosted protease inhibitors - the experience of Polish centers.

Jabłonowska E, Pulik P, Kalinowska A, Gąsiorowski J, Parczewski M, Bociąga-Jasik M, Mularska E, Pulik Ł, Siwak E, Wójcik K.

Arch Med Sci. 2018 Jun;14(4):860-864. doi: 10.5114/aoms.2016.62445. Epub 2016 Sep 22.

6.

The high incidence of late presenters for HIV/AIDS infection in the Lodz province, Poland in the years 2009-2016: we are still far from the UNAIDS 90% target.

Wójcik-Cichy K, Jabłonowska O, Piekarska A, Jabłonowska E.

AIDS Care. 2018 Dec;30(12):1538-1541. doi: 10.1080/09540121.2018.1470306. Epub 2018 May 20.

PMID:
29781305
7.

Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study.

Hatleberg CI, Ryom L, El-Sadr W, Mocroft A, Reiss P, De Wit S, Dabis F, Pradier C, d'Arminio Monforte A, Kovari H, Law M, Lundgren JD, Sabin CA; Data Collection of Adverse Events of Anti-HIV drugs (D:A:D) Study group.

J Int AIDS Soc. 2018 Mar;21(3). doi: 10.1002/jia2.25083.

8.

Intestinal Barrier Impairment and Immune Activation in HIV-Infected Advanced Late Presenters are Not Dependent on CD4 Recovery.

Wójcik-Cichy K, Piekarska A, Jabłonowska E.

Arch Immunol Ther Exp (Warsz). 2018 Aug;66(4):321-327. doi: 10.1007/s00005-018-0508-8. Epub 2018 Feb 21.

PMID:
29468256
9.

Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe.

Santos JR, Cozzi-Lepri A, Phillips A, De Wit S, Pedersen C, Reiss P, Blaxhult A, Lazzarin A, Sluzhynska M, Orkin C, Duvivier C, Bogner J, Gargalianos-Kakolyris P, Schmid P, Hassoun G, Khromova I, Beniowski M, Hadziosmanovic V, Sedlacek D, Paredes R, Lundgren JD; EuroSIDA study group.

HIV Med. 2018 May;19(5):324-338. doi: 10.1111/hiv.12581. Epub 2018 Feb 1.

PMID:
29388732
10.

Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort.

Roen A, Laut K, Pelchen-Matthews A, Borodulina E, Caldeira L, Clarke A, Clotet B, d'Arminio Monforte A, Fätkenheuer G, Gatell Artigas JM, Karpov I, Kuznetsova A, Kyselyova G, Mozer-Lisewska I, Mulcahy F, Ragone L, Scherrer A, Uzdaviniene V, Vandekerckhove L, Vannappagari V, Ostergaard L, Mocroft A; EuroSIDA study.

HIV Med. 2018 Apr;19(4):252-260. doi: 10.1111/hiv.12573. Epub 2017 Dec 22.

PMID:
29271606
11.

Progression of coronary artery disease in a HIV-infected patient previously treated for ascending aorta aneurysm.

Zwoliński R, Kamerys J, Jabłonowska E, Marcinkiewicz A, Jaszewski R, Kręcki R, Jegier B.

Kardiochir Torakochirurgia Pol. 2017 Sep;14(3):211-213. doi: 10.5114/kitp.2017.70539. Epub 2017 Sep 30. No abstract available.

12.

Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens.

Cozzi-Lepri A, Zangerle R, Machala L, Zilmer K, Ristola M, Pradier C, Kirk O, Sambatakou H, Fätkenheuer G, Yust I, Schmid P, Gottfredsson M, Khromova I, Jilich D, Flisiak R, Smidt J, Rozentale B, Radoi R, Losso MH, Lundgren JD, Mocroft A; EuroSIDA Study Group.

HIV Med. 2018 Feb;19(2):102-117. doi: 10.1111/hiv.12557. Epub 2017 Oct 6.

13.

The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people.

Shepherd L, Borges ÁH, Harvey R, Bower M, Grulich A, Silverberg M, Weber J, Ristola M, Viard JP, Bogner JR, Gargalianos-Kakolyris P, Mussini C, Mansinho K, Yust I, Paduta D, Jilich D, Smiatacz T, Radoi R, Tomazic J, Plomgaard P, Frikke-Schmidt R, Lundgren J, Mocroft A; EuroSIDA in EuroCOORD.

HIV Med. 2018 Feb;19(2):90-101. doi: 10.1111/hiv.12546. Epub 2017 Aug 31.

PMID:
28857427
14.

Meeting the WHO 90% target: antiretroviral treatment efficacy in Poland is associated with baseline clinical patient characteristics.

Parczewski M, Siwak E, Leszczyszyn-Pynka M, Cielniak I, Burkacka E, Pulik P, Witor A, Muller K, Zasik E, Grzeszczuk A, Jankowska M, Lemańska M, Olczak A, Grąbczewska E, Szymczak A, Gąsiorowski J, Szetela B, Bociąga-Jasik M, Skwara P, Witak-Jędra M, Jabłonowska E, Wójcik-Cichy K, Kamerys J, Janczarek M, Krankowska D, Mikuła T, Kozieł K, Bielec D, Stempkowska J, Kocbach A, Błudzin W, Horban A.

J Int AIDS Soc. 2017 Jul 17;20(1):21847. doi: 10.7448/IAS.20.1.21847.

15.

Efficacy and safety of nucleoside-sparing regimen based on raltegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients.

Jabłonowska E, Pulik P, Kalinowska A, Gąsiorowski J, Parczewski M, Bociąga-Jasik M, Pulik Ł, Siwak E, Wójcik K.

J Med Virol. 2017 Dec;89(12):2122-2129. doi: 10.1002/jmv.24826. Epub 2017 Aug 31.

PMID:
28390164
16.

Expanding HIV-1 subtype B transmission networks among men who have sex with men in Poland.

Parczewski M, Leszczyszyn-Pynka M, Witak-Jędra M, Szetela B, Gąsiorowski J, Knysz B, Bociąga-Jasik M, Skwara P, Grzeszczuk A, Jankowska M, Barałkiewicz G, Mozer-Lisewska I, Łojewski W, Kozieł K, Grąbczewska E, Jabłonowska E, Urbańska A.

PLoS One. 2017 Feb 24;12(2):e0172473. doi: 10.1371/journal.pone.0172473. eCollection 2017.

17.

Prevalence of Transmitted Drug-Resistance Mutations and Polymorphisms in HIV-1 Reverse Transcriptase, Protease, and gp41 Sequences Among Recent Seroconverters in Southern Poland.

Smoleń-Dzirba J, Rosińska M, Kruszyński P, Bratosiewicz-Wąsik J, Wojtyczka R, Janiec J, Szetela B, Beniowski M, Bociąga-Jasik M, Jabłonowska E, Wąsik TJ, The Cascade Collaboration In EuroCoord A.

Med Sci Monit. 2017 Feb 7;23:682-694.

18.

Interactions of Lipidic Cubic Phase Nanoparticles with Lipid Membranes.

Jabłonowska E, Nazaruk E, Matyszewska D, Speziale C, Mezzenga R, Landau EM, Bilewicz R.

Langmuir. 2016 Sep 20;32(37):9640-8. doi: 10.1021/acs.langmuir.6b01746. Epub 2016 Aug 31.

PMID:
27550742
19.

Hepatic expression of miR-122 and antioxidant genes in patients with chronic hepatitis B.

Wójcik K, Piekarska A, Szymańska B, Jabłonowska E.

Acta Biochim Pol. 2016;63(3):527-31. doi: 10.18388/abp.2015_1216. Epub 2016 Jul 8.

20.

Adherence to antiviral therapy in HIV or HBV-infected patients.

Wójcik K, Piekarska A, Jabłonowska E.

Przegl Epidemiol. 2016;70(1):27-32, 115-8. English, Polish.

Supplemental Content

Loading ...
Support Center